Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lipegfilgrastim

Drug Profile

Lipegfilgrastim

Alternative Names: GlycoPEG-GCSF; GlycoPEGylated G-CSF; GlycoPEGylated granulocyte colony-stimulating factor; Long-acting G-CSF - BioGeneriX/Teva; Long-acting Granulocyte Colony Stimulating Factor - BioGeneriX/Teva; Lonquex; XM-22

Latest Information Update: 19 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioGeneriX; Neose Technologies
  • Developer BioGeneriX; Teva Pharmaceutical Industries
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 19 Oct 2018 Efficacy and adverse events data from the phase III AVOID trial in Neutropenia presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 24 Apr 2018 Merckle GmbH completes the AVOID phase III trial in Neutropenia (In the elderly, Chemotherapy-induced) in Italy (SC) (EudraCT2013-001284-23) (NCT02044276)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neutropenia(In adolescents, In children, Chemotherapy-induced) in Bulgaria (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top